Plasma levels of soluble TNF receptors 1 and 2 after tDCS and sertraline treatment in major depression: Results from the SELECT-TDCS trial

Brunoni, André R.; Machado‐Vieira, Rodrigo; Sampaio-Júnior, Bernardo; Vieira, Érica Leandro Marciano; Valiengo, Leandro; Lotufo, Paulo A.; Carvalho, André F.; Cho, Hyong Jin; Gattaz, Wagner F.; Teixeira, Antônio Lúcio

doi:10.1016/j.jad.2015.07.006

Cited by 22 publications

(17 citation statements)

References 24 publications

(28 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The ketamine-induced reduction of pro-inflammatory compounds such as resistin suggested that resistin could potentially transduce some of the putative anti-inflammatory properties of ketamine. Previous studies had found that sTNFR1 correlated with baseline severity of depression (Brunoni et al, 2015, Grassi-Oliveira et al, 2009), but this finding was not always consistent (Diniz et al, 2010). Other reports showed that sTNFR1 levels correlated significantly with clinical response (Himmerich et al, 2006) but, again, the findings were not consistent (Brunoni, Machado-Vieira, 2015, Teixeira et al, 2015).…”

Section: Discussionmentioning

confidence: 78%

“…Previous studies had found that sTNFR1 correlated with baseline severity of depression (Brunoni et al, 2015, Grassi-Oliveira et al, 2009), but this finding was not always consistent (Diniz et al, 2010). Other reports showed that sTNFR1 levels correlated significantly with clinical response (Himmerich et al, 2006) but, again, the findings were not consistent (Brunoni, Machado-Vieira, 2015, Teixeira et al, 2015). However, the fact that a previous study reported that baseline sTNFR1 levels correlated positively with depression rating scale scores suggested that this compound might play a significant role in the pathophysiology of depressive illness.…”

Section: Discussionmentioning

confidence: 78%

See 1 more Smart Citation

Change in cytokine levels is not associated with rapid antidepressant response to ketamine in treatment-resistant depression

Park

Newman

Gold

et al. 2017

Journal of Psychiatric Research

Self Cite

View full text Add to dashboard Cite

Several pro-inflammatory cytokines have been implicated in depression and in antidepressant response. This exploratory analysis assessed: 1) the extent to which baseline cytokine levels predicted positive antidepressant response to ketamine; 2) whether ketamine responders experienced acute changes in cytokine levels not observed in non-responders; and 3) whether ketamine lowered levels of pro-inflammatory cytokines, analogous to the impact of other antidepressants. Data from double-blind, placebo-controlled studies of patients with major depressive disorder (MDD) or bipolar disorder (BD) who received a single infusion of sub-anesthetic dose ketamine were used (N=80). Plasma levels of the eight cytokines were measured at baseline and at 230 minutes, 1 day, and 3 days post-ketamine. A significant positive correlation was observed between sTNFR1 and severity of depression at baseline. Cytokine changes did not correlate with changes in mood nor predict mood changes associated with ketamine administration. Ketamine significantly increased IL-6 levels and significantly decreased sTNFR1 levels. IL-6 and TNF-α levels were also significantly higher—and sTNFR1 levels were significantly lower—in BD compared to MDD subjects. The functional significance of this difference is unknown. Changes in cytokine levels post-ketamine were not related to antidepressant response, suggesting they are not a primary mechanism involved in ketamine’s acute antidepressant effects. Taken together, the results suggest that further study of cytokine levels is warranted to assess their potential role as a surrogate outcome in the rapid antidepressant response paradigm.

show abstract

Section: Discussionmentioning

confidence: 78%

Section: Discussionmentioning

confidence: 78%

Change in cytokine levels is not associated with rapid antidepressant response to ketamine in treatment-resistant depression

Park

Newman

Gold

et al. 2017

Journal of Psychiatric Research

Self Cite

View full text Add to dashboard Cite

show abstract

“…From the twelve manuscripts, three found association of low responsiveness with high levels of all the investigated pro-inflammatory markers; three found non-association of responsiveness of depression to SSRI for all the investigated markers and one found association of low levels of inflammatory levels with low responsiveness for all the investigated markers. It should be noted that among the studies that found non-association for all the investigated markers, two manuscripts were from the same sample 22,28 , while all manuscripts that found an association of low responsiveness with high levels of all the investigated pro-inflammatory markers were from different samples. These data, focusing on SSRI as a group, give some support to the hypothesis that high levels of pro-inflammatory markers at baseline might predict low responsiveness do SSRI.…”

Section: Baseline Inflammatory Markers As Predictors Of Antidepressanmentioning

confidence: 99%

“…Two studies found no association between responsiveness to treatment and baseline levels of inflammatory markers 22,28 . They were conducted with the same sample at the baseline of a randomized double blind clinical trial comparing sertraline to electrical current stimulation.…”

mentioning

confidence: 98%

“…Measured inflammatory markers included IL-2, IL-4, IL-6, IL-10, IL-17A, IFN-γ, and TNF-α. In the study of 2014, Brunoni et al 22 assessed the cytokines using blood samples and flow cytometry (Cytometric Bead Array Human Th1/Th2/Th17 Kit); whereas in the study of 2015, Brunoni et al 28 assessed the TNF receptors using a sandwich enzyme-linked immunosorbent assay (ELISA). …”

mentioning

confidence: 99%

See 1 more Smart Citation

Marcadores inflamatórios como fatores preditivos para o efeito antidepressivo dos inibidores seletivos da recaptura de serotonina (ISRS)

Corradi¹,

Lisboa²,

Fráguas

2017

Rev. Med. (São Paulo)

View full text Add to dashboard Cite

Corradi MA, Lisboa AB, Fraguas Junior R. Inflammatory markers as predictive factors for selective serotonin reuptake inhibitors (SSRI) antidepressant effect / Marcadores inflamatórios como fatores preditivos para o efeito antidepressivo dos inibidores seletivos da recaptura de serotonina (ISRS). Rev Med (São Paulo) ABSTRACT:Introduction: Data have supported the influence of inflammation in the pathophysiology of depression and also the influence of depression in the development of a proinflammatory state. Major depressive disorder (MDD), the core depressive condition, has selective serotonin reuptake inhibitors (SSRI) as its first line pharmacological treatment. Efforts have been made to identify predictive factors for the responsiveness to SSRI. Therefore, we conducted this review to evaluate the hypothesis that baseline levels of inflammatory markers predict the responsiveness of MDD to SSRI treatment. Methods: A search in the PubMed database was made including the keywords ("SSRI" or "sertraline" or "citalopram" or "fluvoxamine" or "escitalopram" or "fluoxetine" or "paroxetine") and ("cytokines" or "CRP" or "TNF" or "inflammatory") and ("major depressive disorder" or "major depression"). Results: The search retrieved 245 manuscripts, from which 12 fulfilled our inclusion criteria. The analysis of these manuscripts suggested that high levels of interleukin-6 (IL-6), interleukin-1β (IL-1β), tumor necrosis factor-alpha (TNF-α) and c-reactive protein (CRP) at baseline might predict low responsiveness of MDD to SSRI treatment. Confounders such as cognitive impairment, chronicity and severity of depression, melancholic subtype, age and gender were not systematically included in the studies. Conclusion: Findings of this review suggest that high levels of pro-inflammatory markers at baseline might predict low responsiveness of MDD to SSRI treatment. Studies with adequate control for confounders are needed.Keywords: Cytokines; Depression; Inflammation; Serotonin uptake inhibitors; Biomarkers; Predictive value of tests. RESUMO:A influência da inflamação na fisiopatologia da depressão e o papel da depressão no desenvolvimento de um estado pró-inflamatório têm sido apoiados por diversos estudos. O transtorno depressivo maior (TDM), principal diagnóstico de depressão, tem os inibidores seletivos da recaptação de serotonina (ISRS) como tratamento farmacológico de primeira linha. Esforços têm sido feitos para identificar fatores preditivos da responsividade ao tratamento antidepressivo os ISRS. Portanto, esta revisão tem como objetivo avaliar a hipótese de que níveis basais de marcadores inflamatórios predizem a responsividade do TDM ao tratamento com ISRS. Métodos: Pesquisamos o banco de dados PubMed, incluindo as palavras-chave ("ISRS" ou "sertralina" ou "citalopram" ou "fluvoxamina" ou "escitalopram" ou "fluoxetina" ou "paroxetina") e ("citocinas" ou "CRP" ou "TNF" ou "inflamatório") e ("transtorno depressivo maior" ou "depressão maior"). Resultados: A pesquisa identificou 245 manuscritos, dos quais 12 satisfizeram os...

show abstract

Association of Molecular Senescence Markers in Late-Life Depression With Clinical Characteristics and Treatment Outcome

et al. 2022

View full text Add to dashboard Cite

IMPORTANCE Many older adults with depression do not experience remission with antidepressant treatment, and markers of cellular senescence in late-life depression (LLD) are associated with greater severity of depression, greater executive dysfunction, and higher medical illness burden.Since these clinical characteristics are associated with remission in LLD, molecular and cellular senescence abnormalities could be a possible biological mechanism underlying poor treatment response in this population. OBJECTIVE To examine whether the senescence-associated secretory phenotype (SASP) index was associated with the likelihood of remission from a depressive episode in older adults. DESIGN, SETTING, AND PARTICIPANTSA nonrandomized, open-label clinical trial was conducted

show abstract

Plasma levels of soluble TNF receptors 1 and 2 after tDCS and sertraline treatment in major depression: Results from the SELECT-TDCS trial

Cited by 22 publications

References 24 publications

Change in cytokine levels is not associated with rapid antidepressant response to ketamine in treatment-resistant depression

Change in cytokine levels is not associated with rapid antidepressant response to ketamine in treatment-resistant depression

Marcadores inflamatórios como fatores preditivos para o efeito antidepressivo dos inibidores seletivos da recaptura de serotonina (ISRS)

Association of Molecular Senescence Markers in Late-Life Depression With Clinical Characteristics and Treatment Outcome

Contact Info

Product

Resources

About